Acasti Pharma Inc. (NASDAQ:ACST)- Healthcare Stocks Under Profitability Radar: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Acasti Pharma Inc. (NASDAQ:ACST) presented as an active mover, shares shows upbeat performance surged 14.66% to traded at $1.33 in most recent trading session. The firm has floated short ratio of 0.05%, hold to candle to sentiment indicator of Short Ratio, its stand at 0.03.

Acasti Pharma Inc. (ACST) reported that Linda O’Keefe has been named chief financial officer. Ms. O’Keefe brings to Acasti over 30 years of financial experience in the life sciences, manufacturing and business service sectors. As part of the company’s strategy to operate independently of parent company Neptune Technologies & Bioressources Inc., Mario Paradis has resigned as chief financial officer from Acasti to focus solely on his role as vice president and chief financial officer of Neptune.

“We appreciate Mario’s commitment to Acasti and wish him all the best as he dedicates his time to serving as Neptune’s chief financial officer,” said Jan D’Alvise, president and CEO of Acasti.

Usually, financial analysts consider return on equity ratios in the 15-20% range as an attractive level of investment quality. Narrow down focus to firm performance, its weekly performance was 17.70% and monthly performance was 9.02%. The stock price of ACST is moving up from its 20 days moving average with 2.15% and isolated negatively from 50 days moving average with -1.73%.

Following analysis criteria, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) attains noticeable attention, it an ascending 4.08% to traded at $1.53. ARNA attains analyst recommendation of 2.70 on scale of 1-5 with week’s performance of 4.79%.

The firm has noticeable returns on equity ratio of -339.10%, which shows how much profit each dollar of ordinary stockholders’ equity generates. The returns on investment very popular metric among passive investors, it stands at -84.70%. The -39.50% returns on assets presents notable condition of firm. Mostly ROA known as a comparative measure, it is best to compare it against a firm’s previous ROA numbers or the ROA of a same firm.

To find out the technical position of ARNA, it holds price to book ratio of 153.00 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. ARNA is presenting price to cash flow of 3.76.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *